Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/943
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,Immunomodulatory Oligonucleotide
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21890455
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Sensitivity | true |
| Immunomodulatory Oligonucleotide | Sensitivity | true |